Ventrinaya

VentriNaya develops off-the-shelf regenerative gene and cell therapy platforms to treat cardiovascular diseases, focusing on preventing rehospitalization in heart failure patients. The company utilizes two primary approaches: Cyclin A2 gene therapy (VN-100) and placental CDX2+ stem cell therapy (VN-101) to regenerate injured hearts post-myocardial infarction. These single-dose solutions aim to provide long-term efficacy aligned with payer priorities.

Traction –/10

HQ unknown

Updated 5 months ago

Funding

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

VentriNaya develops off-the-shelf regenerative gene and cell therapy platforms to treat cardiovascular diseases, focusing on preventing rehospitalization in heart failure patients. The company utilizes two primary approaches: Cyclin A2 gene therapy (VN-100) and placental CDX2+ stem cell therapy (VN-101) to regenerate injured hearts post-myocardial infarction. These single-dose solutions aim to provide long-term efficacy aligned with payer priorities.